000			02117cam a2200349 a 4500
003			EG-GiCUC
005			20250223031103.0
008			141103s2014 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.14.M.Sc.2014.Al.R
100	0		_aAli Mahdi Alhaddar Alsakkaf
245	1	4	_aThe role of neoadjuvant chemotherapy in surgical decision making for patients with breast cancer during the period from 2008 to 2011 / _cAli Mahdi Alhaddar Alsakkaf ; Supervised Sayed Ahmed Marei , Wessam Ali Elsherif , Omar Sherif Omar
246	1	5	_aدور العلاج الكيميائى الأولى فى صنع القرار الجراحى للمرضى المصابين بسرطان الثدى خلال الفترة من ٢٠٠٨إلى ٢٠١١
260			_aCairo : _bAli Mahdi Alhaddar Alsakkaf , _c2014
300			_a78 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of General Surgery
520			_aBreast cancer is the most common cancer among women, where there is more than 1 million women are diagnosed with breast cancer and more than 400000 die from it. Treatment of Breast cancer can be classified into local therapy like surgery and radiation and systemic therapy like chemotherapy and hormonal therapy. Neoadjuvant (or pre operative) chemotherapy is being increasingly used for the treatment of breast cancer. Response to neoadjuvant chemotherapy may convert an inoperable breast cancer to an operable tumor. By downsizing the tumor, neoadjuvant chemotherapy also increases the possibility of breast conserving therapy in larger number of patient
530			_aIssued also as CD
653		4	_aBreast cancer
653		4	_aGeneral surgery
653		4	_aNeoadjuvant chemotherapy
700	0		_aOmar Sherif Omar , _eSupervisor
700	0		_aSayed Ahmed Marei , _eSupervisor
700	0		_aWessam Ali Elsherif , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c48103 _d48103